BRAF and lymphoma: A phase II study in 2020 conducted on solid tumors and lymphomas with non-V600 BRAF mutations did not show promising results for trametinib (out of 32 patients, only one with breast ductal adenocarcinoma and a BRAF G469E mutation showed a partial response) [143].